Literature DB >> 29625176

High doses of Antisecretory Factor stop diarrhea fast without recurrence for six weeks post treatment.

Shakila Zaman1, Khalida Aamir2, Lars Å Hanson3, Stefan Lange4.   

Abstract

BACKGROUND: Diarrheal illnesses in young children cause morbidity and preventable deaths in developing countries. We evaluated two high doses of Salovum® [Antisecretory Factor] to treat diarrhea in young children and followed up for recurrence 6 weeks post treatment.
METHODS: Forty children, 6-24 months old, admitted with acute diarrhea, to the Outpatient Department of Children's Hospital in Lahore, Pakistan were selected. The patients were randomly allocated to either Group A given 2 sachets, or to Group B, given 4 sachets. Each sachet contained 4gram of Salovum® and was mixed with Oral Rehydration Salt solution. This mixture was administered perorally within the first 30min of treatment. The trained nursing staff observed them for number of stools and consistency over every half hour for a total of 4hours. Follow up for 6 weeks was done daily by telephone, or visits by the mothers. The results demonstrate that Salovum provides a protective effect irrespective of the diarrhea causes.
RESULTS: Group B, given 4 sachets of Salovum® showed improved fecal consistency in 80% of the children compared to 50% in Group A within 30minutes of treatment, p=0.004. The number of diarrheal stools decreased over this time from seven to one/two over 4hours in the two groups [p=0.234]. None of the children showed a recurrence of diarrhea over the follow up period.
CONCLUSION: Peroral high doses of Salovum® rapidly and safely counteract diarrhea in children followed by a diarrhea-free period of 6 weeks.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Antisecretory Factor; Developing country; Follow up period; Paediatric diarrheal disease; Recovery time

Mesh:

Substances:

Year:  2018        PMID: 29625176     DOI: 10.1016/j.ijid.2018.03.015

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  5 in total

1.  Elevated intracranial pressure after head trauma can be suppressed by antisecretory factor-a pilot study.

Authors:  Kliment Gatzinsky; Ewa Johansson; Eva Jennische; Merna Oshalim; Stefan Lange
Journal:  Acta Neurochir (Wien)       Date:  2020-05-22       Impact factor: 2.216

Review 2.  Nutraceuticals for Peripheral Vestibular Pathology: Properties, Usefulness, Future Perspectives and Medico-Legal Aspects.

Authors:  Giuseppe Chiarella; Gianmarco Marcianò; Pasquale Viola; Caterina Palleria; Davide Pisani; Vincenzo Rania; Alessandro Casarella; Alessia Astorina; Alfonso Scarpa; Massimiliano Esposito; Monica Salerno; Nunzio Di Nunno; Matteo Bolcato; Amalia Piscopo; Erika Cione; Giovambattista De Sarro; Giulio Di Mizio; Luca Gallelli
Journal:  Nutrients       Date:  2021-10-18       Impact factor: 6.706

3.  Effect of antisecretory factor, given as a food supplement to adult patients with severe traumatic brain injury (SASAT): protocol for an exploratory randomized double blind placebo-controlled trial.

Authors:  David Cederberg; Bradley M Harrington; Adriaan Johannes Vlok; Peter Siesjö
Journal:  Trials       Date:  2022-04-23       Impact factor: 2.728

4.  Involvement of GABAA receptors containing α6 subtypes in antisecretory factor activity on rat cerebellar granule cells studied by two-photon uncaging.

Authors:  Virginia Bazzurro; Elena Gatta; Elena Angeli; Aroldo Cupello; Stefan Lange; Eva Jennische; Mauro Robello; Alberto Diaspro
Journal:  Eur J Neurosci       Date:  2022-07-20       Impact factor: 3.698

5.  Changes in Antisecretory Factor in Human Milk During the Postpartum and Length of Gestation.

Authors:  Anna Gustafsson; Ewa Johansson; Ewa Henckel; Stefan Lange; Kajsa Bohlin
Journal:  J Hum Lact       Date:  2021-06-01       Impact factor: 2.219

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.